Scholar Rock Holding Corporation
SRRK
Rangering i aksjer
#3510
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to... Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
Aksjekurs
$40.31
Markedsverdi
$4.91B
Endring (1 dag)
1.02%
Endring (1 år)
44.26%
Land
US
Handel Scholar Rock Holding Corporation (SRRK)
Kategori
Healthcare
EPS for Scholar Rock Holding Corporation (SRRK)
EPS per June 2026 TTM: $-3.31
Ifølge de siste økonomiske rapportene og aksjekursen til Scholar Rock Holding Corporation er selskapets nåværende EPS (TTM) $-3.31. Ved slutten av 2023 hadde selskapet en EPS på $-1.99, en nedgang sammenlignet med EPS-en i 2022 som var $-2.21.
EPS-historikk for Scholar Rock Holding Corporation fra 2016 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-3.31 | 34.01% |
| 2024 | $-2.47 | 24.12% |
| 2023 | $-1.99 | -9.95% |
| 2022 | $-2.21 | -38.44% |
| 2021 | $-3.59 | 29.60% |
| 2020 | $-2.77 | 53.89% |
| 2019 | $-1.80 | -42.86% |
| 2018 | $-3.15 | 125.00% |
| 2017 | $-1.40 | 53.85% |
| 2016 | $-0.91 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -623.26% |
US
|
|
| $-7.98 | 141.09% |
US
|
|
| $-5.29 | 59.82% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -938.07% |
NL
|
